The firm also said the move, which will be finalised in December, is part of an effort to refocus its US drug business on key therapetutic areas like oncology, diabetes and atrial fibrillation.
News of the cuts, which will primarily impact Sanofi’s sales team according to media reports, comes as the French drugmajor battles to take control of Genzyme in a move most observers suggest is designed to replenish its patent threatened pipeline.
Sanofi employs 13,000 people in the US across its Pasteur, BiPar and Chattem businesses, some 6,900 of who work in pharmaceutical operations.